36263-67-9

Usage

Structure

Cyclohexane ring with a carboxylic acid group (-COOH) at position 1 and a 4-ethoxyphenyl group attached to the carbon at position 4.

Derivative of

Cyclohexane-1-carboxylic acid

Functional groups

Carboxylic acid (-COOH) and phenyl (C6H5) with an ethoxy (-OCH2CH3) substituent.

Use in organic synthesis

Building block for creating various organic compounds.

Application in pharmaceutical research

Potential use in the development of new drugs and pharmaceuticals.

Versatility

The addition of the ethoxyphenyl group alters the properties of the original cyclohexane-1-carboxylic acid, expanding its potential applications.

Importance

An important chemical compound with potential uses in various industries, including pharmaceuticals, materials science, and chemical research.

Downstream Products

• 36263-77-1 6β-[1-(4-ethoxy-phenyl)-cyclohexanecarbonylamino]-penicillanic acid 
• 122364-43-6 (5R,6R,7R)-7-{[1-(4-Ethoxy-phenyl)-cyclohexanecarbonyl]-amino}-3-methyl-5,8-dioxo-5λ⁴-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 108098-34-6 (6R,7R)-7-{[1-(4-Ethoxy-phenyl)-cyclohexanecarbonyl]-amino}-3-methyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 

Relevant academic research and scientific papers

CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or - C(=O)-; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.